Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775695 | 0.80 | GABRA1 (0.35) | GRM2 | |
| SCHEMBL21937624 | 0.79 | GRM2 (0.41) | GRM2 | |
| SCHEMBL9941587 | 0.78 | DDB1 (0.44) | GRM2CNR1ACHECNR2ADORA2A | |
| SCHEMBL27406455 | 0.77 | GRM2 (0.49) | GRM2ACACBCNR1ACHECNR2 | |
| SCHEMBL25832864 | 0.77 | CHRM2 (0.41) | GRM2CHRM2CHRM1CHRM3MAPT | |
| SCHEMBL26141100 | 0.77 | GABRA1 (0.40) | MAPT | |
| SCHEMBL15687444 | 0.75 | GRM2 (0.40) | GRM2ACACBCNR1ACHECNR2 | |
| SCHEMBL19964477 | 0.73 | GABRA1 (0.36) | MAPT | |
| SCHEMBL30860962 | 0.73 | GRM2 (0.42) | GRM2ACACBCNR1ACHECNR2 | |
| SCHEMBL27227914 | 0.73 | GRM2 (0.42) | GRM2ACACBCNR1ACHECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2020047208-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | GRM2 2141/4885ACACB 3016/4885CHRM2 1133/4885 |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | GRM2 2503/4885ACACB 1394/4885CHRM2 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.